Biotech stocks can offer significant upside because they have high-growth potential if their drug candidates succeed in trials or gain FDA approval. For long-term biotech investors who can accept the risk of clinical-stage drugmakers, Eledon (ELDN) and Acumen (ABOS) are exciting opportunities to look at. However, given that they are penny stocks, they might be suitable for investors with a high-risk appetite.
